



OPEN

Cyclical aggregation extends in vitro expansion potential of human mesenchymal stem cells

Brent M. Bijonowski^{1,3}✉, Xuegang Yuan^{1,2}, Richard Jeske¹, Yan Li¹✉ & Samuel C. Grant^{1,2}

Mesenchymal stem cell (MSC)-based therapy has shown great promises in various animal disease models. However, this therapeutic potency has not been well claimed when applied to human clinical trials. This is due to both the availability of MSCs at the time of administration and lack of viable expansion strategies. MSCs are very susceptible to in vitro culture environment and tend to adapt the microenvironment which could lead to cellular senescence and aging. Therefore, extended in vitro expansion induces loss of MSC functionality and its clinical relevance. To combat this effect, this work assessed a novel cyclical aggregation as a means of expanding MSCs to maintain stem cell functionality. The cyclical aggregation consists of an aggregation phase and an expansion phase by replating the dissociated MSC aggregates onto planar tissue culture surfaces. The results indicate that cyclical aggregation maintains proliferative capability, stem cell proteins, and clonogenicity, and prevents the acquisition of senescence. To determine why aggregation was responsible for this phenomenon, the integrated stress response pathway was probed with salubrial and GSK-2606414. Treatment with salubrial had no significant effect, while GSK-2606414 mitigated the effects of aggregation leading to in vitro aging. This method holds the potential to increase the clinical relevance of MSC therapeutic effects from small model systems (such as rats and mice) to humans, and may open the potential of patient-derived MSCs for treatment thereby removing the need for immunosuppression.

The therapeutic potential of human mesenchymal stem cells (MSCs) has been revealed in numerous studies due to their immunomodulatory effects^{1–4}, enhancement of tissue regeneration and angiogenesis in ischemic injuries^{5,6}, and as a potential source of therapeutic exosomes^{7–9}. Yet the in vivo therapeutic potency has been done predominately in animal models which require orders of magnitude fewer cells compared to human subjects. Therefore, MSCs have not been widely applied to clinical trials as expected. One of the major limitations for clinical applications of MSCs is imposed by in vitro scale-up of deliverable cells¹⁰. Additionally, there is a supply disconnect because cells for rodent models can be cultured directly before injection, while clinical studies rely on defrosting ampules of cells and injecting them without proper cellular relaxation¹¹. The majority of in vitro and in vivo studies utilize bone marrow or adipose tissue-derived MSCs due to their relative ease of extraction and density of viable cells¹². Yet there are still too few cells recovered from any one donor. Thus, donor pooling is utilized in order to achieve adequate dosing in certain disease model such as graft-versus-host disease¹³. Ideally, patients would be treated with their own MSCs expanded at a large scale in vitro; however, this is limited because MSCs lose functionality as a result of extended in vitro culture expansion.

MSCs are very sensitive to their microenvironment and could adapt cellular events based on certain physiological cues such as oxygen or biophysical cues such as culture surface stiffness¹⁴. The culture adaption of MSCs can be beneficial under certain conditions such as hypoxia treatment and 3D aggregation culture, which are widely applied to preconditioning of stem cells¹⁵. In other cases, culture adaption to nutrient/oxygen enrichment and in vitro culture leads to cellular senescence or in vitro aging¹¹. The long-term cultured MSCs may exhibit increased senescence, loss of differentiation potential, loss of beneficial secretory profile, and loss of proteostasis, which all contribute to a general loss of stem cell phenotype¹¹. Proteostasis is essential to stem cell function and fate decisions¹⁶. It has been observed that as embryonic stem cells undergo in vitro aging, they gradually lose control over their proteome which further triggers cell death¹⁶. This is a critical control as accumulation of defects in daughter cells would be detrimental to the organism¹⁷. This defect accumulation is postulated as a direct result

¹Department of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Florida State University, 2525 Pottsdamer St., Tallahassee, FL 32310, USA. ²The National High Magnetic Field Laboratory, Florida State University, Tallahassee, FL, USA. ³Present address: University of Münster, Münster, Germany. ✉email: bmb14d@my.fsu.edu; yli4@fsu.edu




Figure 1. Assessment of ASC morphology along with growth kinetics to determine the effects of cyclical aggregation. **(A)** Morphologic assessment revealed the loss of spindle shape in planar expansion, yet morphology was maintained via cyclical aggregation. **(B)** Analysis of ASC doublings and doubling time revealed that while planar cells were able to expand readily during early passages, the cells were eventually outpaced by aggregated cells which also maintained doubling time. Data represents the mean of at least three independent determinations; errors represent the standard error in the mean. * $p < 0.05$.

of a breakdown in the integrated stress response (ISR), which is a complex pathway that recognizes misfolded proteins and initiates a lockdown on protein synthesis, increases folding chaperones, and if proteostasis cannot be recovered, provides signals for autophagy^{17,18}.

However, these effects can be mitigated through the MSC's 3D aggregation process in which cells are integrated into a new cellular environment with a lower modulus similar to human tissue^{19–23}. Additionally, aggregation promotes cell–cell interactions, which create new cell signaling events from either paracrine or biomechanical stimulation^{24–26}. Both mechanisms may contribute to how aggregated MSCs have been shown to enhance multiple cellular functions, such as anti-inflammatory and regenerative potential^{27,28}, stem cell genes^{29,30}, and the increased ISR response³¹. However, cells within the aggregate have reduced proliferative potential, meaning that aggregation alone cannot solve the scale-up problem^{30,32}.

For this reason, the hypothesis that cyclical aggregation of MSCs can extend the ability to counter in vitro culture stress and maintain functionality during in vitro culture expansion compared to planar culture. To accomplish this, early passage human adipose tissue-derived mesenchymal stem cells (hASCs) were either cultured on planar surfaces or cycled between aggregation and planar culture (i.e., cyclic aggregation-passaging or CP) for an equal passage number of planar expansions. Proliferation and population doubling times were recorded along with stem cell functions such as differentiation into adipogenic and osteogenic cells, expression of stem cell genes, and the level of senescence. It was observed that cyclical aggregation resulted in well-maintained proliferative capability, cellular doubling time, MSC morphology, mRNA levels of stem cell genes, the abilities of differentiation into adipocytes and osteoblasts, and reduced β -galactosidase activity over the 12 aggregation-planar expansions. Inhibition of the ISR pathway with GSK-2606414 reversed these effects and hASCs in vitro aged more rapidly. These results illustrate a novel culture method/system by which MSCs can be in vitro expanded while also maintaining functionality in long-term culture; thereby, opening up multiple clinical avenues for treatments that would be otherwise closed due to immunogenicity or functional decline due to MSC senescence.

Results

Aggregation of hASCs maintains naïve morphology and growth kinetics. To assess the effect of aggregation in maintaining cellular properties, the cellular morphology was monitored. Microscopic images revealed that as passage number increased via planar expansion, hASCs gradually lost their characteristic spindle shape (Fig. 1A). Single passage aggregation from passage 8–9 (SP9) and 14–15 (SP15) was able to partially recover the morphology. Cells from cyclical aggregation maintained the spindle shape at passage 15 (CP9) and 27 (CP15) (Fig. 1A and Suppl. Figure S1). Next, cellular proliferation and doubling time were investigated (Fig. 1B). Planar expansion led to an early growth pattern, but eventually cells stopped doubling, showing a




Figure 2. Integrated stress response (ISR) modulation shows that aggregation-induced signaling is responsible for maintenance of stem cell growth kinetics. Cell doublings under ISR response following treatments with (A) salubrinal (5 μ M) and (B) GSK-2606414 (10 μ M), which illustrate that inhibiting ISR results in accelerated cell death. Doubling time of ISR-modulated ASCs: (C) salubrinal (5 μ M) and (D) GSK-2606414 (10 μ M), revealing the ISR effect of cyclical aggregations on stem cell growth. Data represents the mean of at least three independent determinations; errors represent the standard error in the mean. # indicates $p < 0.05$ (planar vs. treatment), % indicates $p < 0.05$ (aggregation vs. treatment), \$ indicates $p < 0.05$ (treated planar vs. treated aggregation).

stagnant population curve. Cyclical aggregation resulted in a continuous growth pattern over the 12 cycles of expansions, showing significantly more cells and a reduced doubling time than planar expansion.

Integrated stress response affects aggregation-based ASC maintenance. Since ISR response is essential to maintaining stem cell function, and our study recently showed that aggregation of MSCs results in a heightened basal ISR response (manuscript submitted), the doubling time was assessed under ISR modulation with salubrinal, a growth arrest and DNA damage-inducible protein (GADD34) inhibitor which prevents ISR elevation, and GSK-2606414 (GSK), a phospho-protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitor which prevents the cells from entering ISR. Treatment with salubrinal had no significant effect on doubling time of aggregates. However, planar cells eventually die after passage 10, showing a significant difference between the treated and untreated groups (Fig. 2A). Treatment with GSK affected both planar and aggregate cultures, and both conditions showed early cell death (Fig. 2B). Doubling times showed similar trend, i.e., aggregate cells treated with salubrinal doubled significantly slower than the untreated condition (Fig. 2C). GSK-treated cells had increased doubling times and the cell numbers dropped immediately, showing a negative doubling time (Fig. 2D). Additionally, planar cells treated with salubrinal exhibited better maintenance of spindle shape morphology up to passage 9 (Suppl. Figure S2), while GSK treatment resulted in accelerated loss of morphology (data not shown). Aggregated cells treated with salubrinal did not show significant change in morphology until CP9 (Suppl. Figure S2).




Figure 3. Assessment of stem cell functionality revealed signs of in vitro aging could be countered with aggregation treatment. **(A)** Quantification of Western blot analysis of stem cell markers Nanog and Sox-2 reveals that planar expansion leads to their loss, and an accumulation of junk protein XBP-1s. Cyclical aggregation increased Nanog and Sox-2 but decreased XBP-1s. **(B)** Colony-forming unit (CFU) assay was utilized to assess stem cell content in total cells, which reveals that planar cells loss this functionality; however, aggregation can retain stem cell content. **(C)** Telomere length was used to measure telomerase activity, a key component of stem cell rejuvenation. **(D)** β -galactosidase activity was used to measure the level of senescence, and a significant increase in activity was observed as passage number increased in planar culture. This could be prevented through cyclical aggregation. Data represents the mean of at least three independent determinations; errors represent the standard error in the mean. * $p < 0.05$, *** $p < 0.001$.

Cyclical aggregation to maintains stemness and decreases senescence. The cells from each time point were analyzed by Western blot. The results revealed that for ASCs under planar expansion, the expression of stem cell markers Nanog and Sox2 significantly decreased with passage number increase (i.e., P4, P9, and P15), and the expression of the spliced misfolded protein signal XBP-1s significantly increased. Single aggregations resulted in a reversal of these trends at P9 and P15. Similarly, cyclically aggregated cells (P9 and P15) demonstrated the increased expression of Nanog and Sox2, and the decreased expression of XBP-1s (Fig. 3A). Next clonogenicity was measured and there was a significant drop in CFU number following planar expansion (P4, P9 and P15) (Fig. 3B and Suppl. Figure S3). Single aggregations did add some clonogenicity but was still significantly reduced compared to P4 ASCs. Cyclical aggregation, however, did not result in a significant change and maintained clonogenicity (Fig. 3B).

Telomere length was used to determine how passaging affects stem cells' ability to replicate indefinitely. No significant trend was revealed for P4 and P9 cells of planar culture, single aggregated SP9 cells, and cyclical aggregated CP5, CP9, and CP15 cells (Fig. 3C). Cellular senescence was measured via senescence-associated β -galactosidase activity (β -gal), which showed a significantly increased activity from 0.521 ± 0.006 relative fluorescence units (RFU)/ng protein in planar P4 cells to 1.556 ± 0.270 RFU/ng protein and 11.040 ± 0.712 RFU/ng protein by passage 9 and 15 respectively. Additionally, single aggregated cells at SP9 exhibited the significantly reduced β -gal activity (0.706 ± 0.181 RFU/ng protein) compared to P9 planar cells, but not to P4 planar cells. Single aggregated cells at SP15 also showed the significantly decreased senescence (3.372 ± 0.191 RFU/ng protein) over the control group (P15 planar cells), yet was still significantly higher than P4 cells. Cyclical aggregation treatment did not significantly affect β -gal activity for cells at either CP6 (0.620 ± 0.062 RFU/ng protein), CP9 (0.529 ± 0.014 RFU/ng protein), or CP15 (0.52 ± 0.001 RFU/ng protein) (Fig. 3D).

Cyclical aggregation retains differentiation potential. A key component of stem cell function is differentiation potential. Adipogenic differentiation was characterized by staining differentiated cells with Oil Red O. Naïve cells showed strong positive staining of encapsulated oil red deposits; however, planar expansion to P9 and P15 resulted in a significant decline in number of oil red spots. Single aggregations had no effect of differentiation potential. Cyclical aggregation showed a similar level of Oil Red O staining to naïve cells (Suppl. Figure S4). Additionally, osteogenic differentiation was performed. ASCs at passage 9 and 15 showed low survival, and decreased differentiation, which was slightly improved with single aggregation. Cyclical aggregation, however, was able to maintain cellular viability and differentiation potential (Suppl. Figure S5).

Rocker-based aggregation for potential process scale up. An alternative aggregation culture can be achieved by wave-motion to generate hASC aggregates as a potential scale-up process in a manner similar to cyclical aggregation (Fig. 4A). Preliminary experiments of aggregation culture of P4 hASCs showed that rocker-




Figure 4. Analysis of static versus dynamic (rocker) aggregate formation in a low-attachment plate. **(A)** Experimental flow: For cyclical aggregation, hASCs were aggregated for two days before being trypsinized and replated until they reach confluence. For planar culture and single aggregation experiment, hASCs were cultured on tissue culture treated surfaces. **(B)** Microscopic images of aggregates formed under static and rocker-based aggregation culture at 24 and 48 h post-seeding. **(C)** Histogram of aggregate diameters for 24 and 48 h for both static and rocker-based aggregation. **(D)** Osteogenic and adipogenic differentiation potential following aggregation under static culture or rocker-based aggregation culture compared with untreated (non-aggregated) cells.

based aggregation results in a narrower aggregate diameter profile than that observed under static aggregation on a low-attachment surface (Fig. 4B,C). This is advantageous as it results in a homogenous population, thus minimizing differential influences of biomechanical stress induced by aggregates of different sizes. Similarly, whether aggregation method would alter differentiation potential was assessed, and no significant change was observed for ASCs using different aggregation methods (Fig. 4D).

Discussion

MSCs pose significant therapeutic benefit; however, they must be expanded to reach the required numbers prior to being used in clinical trials. During in vitro expansion, MSCs rapidly adapt to the nutrient-enriched environment, experience in vitro aging, and eventually become senescent^{33,34}. This work sets out to test whether cyclical aggregation, which has been shown to heighten MSC's beneficial effects^{35–37} and restore naïve cellular function^{38,39}, can preserve MSC properties under long term expansion. Cyclical aggregation-planar expansion is necessary because MSCs lose function during planar expansion but are functionally enhanced during aggregation culture. Yet aggregated cells proliferate slower than planar cells^{40–42}. Additionally, improvements of cellular properties have been shown to last one passage beyond aggregation⁴². By coupling planar expansion with aggregation, cells can be expanded while minimizing accumulated stresses and retaining a more naïve phenotype. This method can be potentially used to scale up MSC aggregates in batches via Wave bioreactors⁴⁰.

Aggregation of ASCs prevents the loss of morphology and maintains cellular kinetics. Most studies utilize early passages of MSCs and ASCs up to passage 6 for experiments, due to loss of function during *in vitro* expansion¹¹. A key hallmark of MSC aging is the loss of stem cell morphology, which was assessed at critical time points before and after the passaging. Images revealed that ASCs lost their characteristic spindle shape during planar expansion. This is in accordance with what has been observed by others^{32,33}. For example, Yang et al. observed that passaging MSCs resulted in loss of cell shape and function as early as passage 5³³. Previously, it has been shown that aggregation of ASCs results in the retention of stem cell morphology⁴¹. This study demonstrates that the cyclical aggregation likewise maintained the spindle morphology.

Beyond morphology, it was observed that the planar-cultured ASCs eventually become stagnant in growth kinetics, resulting in a significant reduction in expansion potential compared to cyclical aggregation. The process of aggregation did result in approximately 40% cell loss with each cycle (data not shown), which may be attributed to lack of proliferation in aggregates, increased caspase activity, and trypsinization^{42,43}. However, ultimately the fact that aggregation maintains ASC proliferation and doubling time outweighs this loss, resulting in overall enhanced proliferation. Bartosh et al. also examined proliferation of MSCs following aggregation compared to planar culture, and observed an initial loss of proliferation ability followed by a spike in proliferation before losing the expansion potential and then returning to planar culture³⁹.

Modulation of ISR reverses aggregation-induced effects. Proteome control is essential to stem cell function¹⁶, and aggregation has been shown to rejuvenate ISR response³⁷ and reestablish cellular function^{17,28,44}. This study also explored if ISR is responsible for the effects observed following cyclical aggregation. As expected, salubrinal had no effect on aggregate culture, which may be attributed to the fact that aggregation already activates ISR, so further elevation of ISR does not affect the aggregated cells. However, there was a significant difference for planar culture with salubrinal-treated and untreated groups. For the first four passages, salubrinal-treated planar cells had similar cell doublings compared to the untreated group. However, after the initial expansion salubrinal-treated cells died off. This can be explained by the fact that ISR prevents protein synthesis. GSK-2606414 prevents PERK signaling and was found to reverse aggregation-induced effects in proliferation. Therefore, under GSK-2606414 treatment, aggregate culture becoming similar to planar-expanded cells. Likewise, planar culture with GSK2606414-treated group accelerated cellular aging effects and led to cell senescence.

Aggregation maintains stem cell markers, clonogenicity, and mitigates senescence. As stem cells age, they gradually lose the expression of stem cell markers such as Nanog and Sox-2. Kapetanou et al. recently assessed how Oct-4, Nanog, and Sox-2 shifted in MSCs from early passage, through middle passage, and into late passage. The authors revealed that all three proteins significantly decreased to at least 50% from early to late passage⁴⁵. This is similar to what has been observed in this study for passages 9 and 15 cells respectively. Aggregation has been shown to significantly increase Oct-4, Nanog, and Sox-2 by at least two-fold^{28,39}. This level of upregulation was not observed in this study, possibly due to the cells being expanded in planar culture for at least one passage following aggregation. The significant observation in this study is that stem cell markers did not decrease over time, but rather are maintained using cyclical aggregation method.

A recent publication by Bertolo et al. assessed how CFU and β -gal activity of MSCs fluctuated following 11 passages, and concluded that CFU decreased, while β -gal activity increased⁴. This is similar to the results observed herein. Aggregation has also been shown previously to increase CFU number, similar to the effects shown here³⁹. Senescence has been shown to be decreased by approximately sevenfold following aggregation²⁸. In current study, β -gal activity was also significantly reduced following aggregation of P9 and P15 hASCs. Additionally, the lack of a significant difference between any cyclical passage and the naïve P4 in stem cell markers, CFU activity, or β -gal activity confirms the hypothesis that cyclical aggregation can maintain stem cell characteristics.

Cyclical aggregation maintains differentiation potential. Differentiation potential of ASCs was measured for adipogenic and osteogenic lineages in this study. Adipogenic differentiation ability was quickly lost by P9 and further degraded by P15. These effects could not be ameliorated by aggregation, showing that while aggregation can improve many functions, it has limitations in dedifferentiation potential. Cyclical aggregation on the other had maintained adipogenic differentiation potential. Similarly, osteogenic differentiation was strong initially, which was maintained by cyclical differentiation. However, planar expansion resulted in decreased cell viability, loss of cellular morphology, and decreased staining of calcium deposits. A similar reduction in adipogenic and osteogenic differentiation potential following planar expansion was observed by Yang et al.³³. For adipogenic differentiation, a significant number of oil droplets at P4 was observed, but the number decreased significantly for P8 cells. This was corroborated by a drop in lipoprotein lipase and peroxisome proliferator-activated receptor gamma (PPAR γ) which are both classical indicators of adipocytes. For osteogenic differentiation, a decrease in cellular viability and a reduction in calcium deposits in P8 cells were observed compared to P4. This was corroborated by a reduction in alkaline phosphatase expression.

Conclusions

The therapeutic potentials of MSCs are undercut by the limitations found in large scale culture expansion for human clinical trials. This study utilized a novel culture strategy by cyclical aggregation and replating MSCs to address this engineering problem. MSCs that undergo this aggregation cycle preserved their stem cell phenotype compared to planar culture. This study also indicated that by perturbing the ISR induced by aggregation, MSCs can be expanded without jeopardizing their functionality. Specifically, cyclical aggregation can maintain cell morphology, growth kinetics, expression of stem cell proteins, clonogenicity, and differentiation ability and thus acts as an anti-senescence strategy during *in vitro* expansion. While more work is needed to further optimize

the cycle of aggregation and planar expansion, this study demonstrates an important culture strategy as it lays the groundwork for creating a new biomanufacturing option for MSCs.

Methods

Culture of hASCs. Frozen hASCs at passage 1, in liquid nitrogen, were obtained from the Tulane Center for Stem Cell Research and Regenerative Medicine (hASCs were isolated from the liposate of de-identified healthy donors at Tulane). Cells from three donors (younger than 60 years of age, and the donors were not directly involved in this study) were used to carry out this study to ensure generalizability and significance of effects. hASCs were expanded with minimum essential medium- α (MEM) (Life Technologies, Carlsbad, CA) supplemented with 1% penicillin/streptomycin (Life Technologies) and 10% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA) to form complete culture media (CCM) on 150-mm tissue culture Petri (TCP) dishes (Corning, Corning, NY) to a density of approximately 2500 cells/cm² in a standard 5% CO₂ incubator. The culture media were changed every 3 days. Cells from passage 4 (P4) were used as initial starting point for all experiments. All culture reagents were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise noted.

Aggregate formation. Once cells reached 90% confluence, the cells were trypsinized and pelleted. The pellet was resuspended in CCM at 1×10^5 cells/mL. The cell suspension was pipetted at 1 mL per well in an ultra-low attachment (ULA) 6-well plate, for a total of 6×10^5 cells. The aggregates were homogenized over 48 h. Multiple aggregates were observed per well. The morphologies and size-distribution of aggregates (100–400 μ m in diameter) can be tracked and imaged with an Olympus IX70 microscope (Center Valley, PA) and were reported in our previous publication⁴⁰. For rocker-based aggregation, The ULA plates were placed on a rocking platform (VWR International, Radnor, PA) in a standard humidified incubator (37 °C, 5% CO₂) under controlled rocking angle of 8° and rocking speeds (i.e., 20 rpm) for 48 h. The rocking conditions generate wave motion of media under shear stress that supports spontaneous aggregation of hMSCs. Cells that went through one aggregation culture was defined as single-aggregation passage (SP).

Cyclical aggregation and replating culture. After 48 h, aggregates were collected from each well, pelleted by centrifuge and washed with phosphate buffer saline (PBS). Then the hASC aggregates were incubated with 0.25% trypsin/ethylenediaminetetraacetic acid (EDTA) (Invitrogen, Grand Island, NY) for 10 min. Gentle pipetting was carried out every 5 min. hASC aggregates were digested into single cell suspension and then pelleted. After centrifugation, cell pellets were resuspended in CCM and counted. Small clusters existed in the suspension and were repleted together with single cells. The cells were replated on 150-mm TCP at a density of ~2500 cells/cm². The process of aggregation and replating was counted as one cycle (or one cyclic-aggregation passage, CP) and the whole process was carried out for 12 cycles (stopped at CP15) to match the passage number of planar culture expansions (P15). For ISR experiments, planar and aggregation cultures were treated with either GSK-2606414 or salubrinal every other passage³¹.

Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. hASCs were washed with ice cold PBS and a cell lifter was utilized to remove cells. Cellular suspension was then pelleted at 800 g for 5 min at 4 °C. Samples were then suspended in RNeasy Mini Kit (Qiagen, Valencia, CA) lysis buffer and homogenized with a Sonic Dismembrator 100 (Fisher Scientific, Hampton, NJ) RNA was then fully extracted according to the kit's instructions. 2 μ g of total RNA was used to carry out Reverse transcription, with anchored oligo-dT primers (Operon, Louisville, KY) and Superscript III (Invitrogen, Grand Island, NY). Specific primers for target genes were designed in the software Oligo Explorer 1.2 (<https://oligo-explorer.software.informer.com/1.2/>, Genelink, Hawthorne, NY). Vinculin was used as an endogenous control for normalization. RT-PCR reactions were performed on an ABI7500 instrument (Applied Biosystems, Foster City, CA), using SYBR Green PCR Master Mix. After amplification, the quality and primer specificity were verified. Variation in gene expression was evaluated using the comparative Ct method: $2^{-(\Delta C_{treatment} - \Delta C_{control})}$, based on the expression of the target gene (normalized to *TUBA*).

Absolute telomere length quantification. Plates containing cells were triple washed with ice-cold PBS before by process according to the Absolute Human Telomere Length Quantification qPCR Assay Kit (Sciencell, Carlsbad, CA). Briefly, purified DNA was acquired using the Quick-DNA/RNA Microprep Plus Kit (Zymo, Irvine, CA) according to the manufacturer's instructions. Samples were run in either with telomere primer or with the included SCR primer. 2 ng of sample DNA were extracted, and reaction mixture was made by adding 2 μ L primer, 10 μ L 2 $\times$ qPCR master mix, and nuclease-free water up to make 20 μ L of mix. Samples were sealed and centrifuged at 1500g for 15 s. At this point the samples were thermocycled in an ABI7500 instrument without ROX passive reference dye. Telomere length was determined by $(Reference\ sample\ telomere\ length) * 2 - (\Delta C_q(TEL) - \Delta C_q(SCR))$.

Senescence-associated β -Galactosidase activity. SA- β -galactosidase activity was measured using with the 96-well cellular Senescence Assay Kit (Biolabs, San Diego, CA) according to the manufacturer's instructions. In brief, cells were seeded at 80% confluence (4500 cells/cm²) in CCM and were cultured as normal overnight. Cells were then washed with ice cold PBS, and 1X Cell Lysis Buffer was added, and the cells were incubated at 4 °C for 5 min before lysates were collected and centrifuged for 10 min at 4 °C and 14,000g. Supernatant was collected, and a bicinchoninic acid assay was run to determine protein content in each sample. 50 μ L of lysate was transferred to a 96-well plate and 50 μ L of 2 $\times$ Assay buffer was added. This was incubated at 37 °C for 2 h,

and 50 μL of sample was added to a black fluorescence safe 96-well plate in triplicate. 200 μL of stop solution was added to each sample and the fluorescence intensity was measured (360 nm Excitation/465 nm Emission).

Western blot assay. The analyzed cells were washed with PBS, and lysed in radio-immunoprecipitation assay (RIPA) buffer (150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8, 2 $\mu\text{g}/\text{mL}$ Aprotinin, 5 $\mu\text{g}/\text{mL}$ Leupeptin, 5 $\mu\text{g}/\text{mL}$ Antipain, 1 mM PMSF protease inhibitor), and homogenized by sonification using a Sonic Dismembrator 100 (Fisher Scientific, Hampton, NJ). Samples were then digested for 20 min on ice, and spun down at 14,000 rpm for 20 min. The supernatant was collected and a Bradford assay was carried out to determine protein concentration. About 20 μg of each sample was denatured at 95 $^{\circ}\text{C}$ in 2 $\times$ Laemmli Sample buffer. Proteins were separated by 15% BIS-Tris-SDS gels and transferred onto a nitrocellulose membrane (Bio-rad, Hercules, CA). The membranes were blocked for 30 min in 3% skim milk (w/v) in Tris-buffered saline (10 mM Tris-HCl, pH 7.5, and 150 mM NaCl) with 0.1% Tween 20 (v/v) (TBST), or in 3% bovine serum albumin in TBST. Membranes were incubated overnight with the primary antibody diluted in the blocking buffer at 4 $^{\circ}\text{C}$. Afterward, the membranes were washed four times for 10 min each with TBST and then incubated with an IR secondary (LI-COR, Lincoln, NE) at 1:10,000 for 180 min at room temperature. Blots were washed another four times and processed using the LI-COR Odyssey (LI-COR). Images were analyzed using ImageJ 1.46r software (<https://imagej.nih.gov/ij/>, National Institutes of Health, USA) and the band density of proteins of interest was normalized to the band density of endogenous control vinculin.

Adipogenic differentiation. The cells were grown to confluence before CCM was switched for Adipogenic Induction media (AI) containing: high glucose DMEM (Gibco, Grand Island, NY), 10% FBS, 1% penicillin/streptomycin, 0.2 mM indomethacin, 0.5 mM isobutyl-1-methyl xanthine, 1 μM dexamethasone, 10 $\mu\text{g}/\text{mL}$ insulin, and 44 mM sodium bicarbonate. The AI media were replaced after two days by Adipogenic Maintenance media (AM) which contains: high glucose DMEM, 10% FBS, 1% penicillin/streptomycin, 10 $\mu\text{g}/\text{mL}$ insulin, and 44 mM sodium bicarbonate. After two more days, AM media were replaced by AI media. This cycle was continued for 28 days. At this point, the plates were washed with PBS and fixed with 10% neutral buffered formalin for 1 h at room temp. Plates were washed again before treated with 60% isopropanol for 5 min. The isopropanol solution was then removed, and Oil Red O suspended in 60% isopropanol was added and incubated at room temperature for 5 min. The plate was then washed under tap water until clear and counter stained with hematoxylin for one minute. After washing with water, the plates were imaged under an Olympus IX70 microscope.

Osteogenic differentiation. The cells were grown to confluence before CCM was switched for osteoblast differentiation media containing: high glucose DMEM (Gibco, Grand Island, NY), 10% FBS, 1% penicillin/streptomycin, 100 mM dexamethasone, 10 mM sodium- β -glycerophosphate, and 0.05 mM ascorbic acid-2-phosphate. The media were changed every three days until day 20. At this point, the plates were washed with PBS and fixed with 10% neutral buffered formalin for 1 h at room temperature. Von Kossa staining was used to identify the matrix mineralization after osteogenic differentiation. The cells were washed before treated with 5% silver nitrate under ultraviolet light for 90 min. After washing three times with deionized water, the plates were treated with 5% sodium thiosulfate for 5 min, and counterstained with Nuclear Fast Red. The cells were then imaged under an Olympus IX70 microscope.

Colony forming unit (CFU) assay. The analyzed cells were seeded in CCM at 12 cells/ cm^2 and cultured in a 5% CO_2 incubator at 37 $^{\circ}\text{C}$ for 14 days. The cells were then triple washed with PBS and stained with 0.5% crystal violet (in methanol) for 5 min. The cells were washed with PBS and the numbers of colonies were counted.

Statistics. A two-tailed Student's t test was used to compare two groups, and for multiple group comparison a one-way analysis of variance with Tukey's post-hoc analysis was performed using SPSS software (<https://www.spss.com>, Chicago, IL, USA). All data are presented as a mean value with its standard deviation indicated (mean $\pm$ SD). Differences were considered to be statistically significant when the p values were <0.05 .

Received: 3 May 2020; Accepted: 9 November 2020

Published online: 24 November 2020

References

1. Espagnolle, N., Balguerie, A., Arnaud, E., Sensebe, L. & Varin, A. CD54-mediated interaction with pro-inflammatory macrophages increases the immunosuppressive function of human mesenchymal stromal cells. *Stem Cell Rep.* **8**, 961–976 (2017).
2. Petrie Aronin, C. E. & Tuan, R. S. Therapeutic potential of the immunomodulatory activities of adult mesenchymal stem cells. *Birth Defects Res. C Embryo Today* **90**, 67–74 (2010).
3. Wang, L. T. *et al.* Differentiation of mesenchymal stem cells from human induced pluripotent stem cells results in downregulation of c-Myc and DNA replication pathways with immunomodulation toward CD4 and CD8 cells. *Stem Cells* **36**, 903–914 (2018).
4. Bertolo, A. *et al.* An in vitro expansion score for tissue-engineering applications with human bone marrow-derived mesenchymal stem cells. *J. Tissue Eng. Regen. Med.* **10**, 149–161 (2016).
5. Bhang, S. H. *et al.* Angiogenesis in ischemic tissue produced by spheroid grafting of human adipose-derived stromal cells. *Biomaterials* **32**, 2734–2747 (2011).
6. Song, W. J. *et al.* TSG-6 secreted by human adipose tissue-derived mesenchymal stem cells ameliorates dss-induced colitis by inducing M2 macrophage polarization in mice. *Sci. Rep.* **7**, 5187 (2017).

7. Cosenza, S. *et al.* Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. *Theranostics* **8**, 1399–1410 (2018).
8. Keshitkar, S., Azarpira, N. & Ghahremani, M. H. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. *Stem Cell Res. Ther.* **9**, 63 (2018).
9. Vilaca-Faria, H., Salgado, A. J. & Teixeira, F. G. Mesenchymal stem cells-derived exosomes: A new possible therapeutic strategy for Parkinson's disease? *Cells* **8**, 118 (2019).
10. Tsai, A. C., Jeske, R., Chen, X., Yuan, X. & Li, Y. Influence of microenvironment on mesenchymal stem cell therapeutic potency: from planar culture to microcarriers. *Front. Bioeng. Biotechnol.* **8**, 640 (2020).
11. Yin, J. Q., Zhu, J. & Ankrum, J. A. Manufacturing of primed mesenchymal stromal cells for therapy. *Nat. Biomed. Eng.* **3**, 90–104 (2019).
12. Fitzsimmons, R. E. B., Mazurek, M. S., Soos, A. & Simmons, C. A. Mesenchymal stromal/stem cells in regenerative medicine and tissue engineering. *Stem Cells Int.* **2018**, 8031718 (2018).
13. Galipeau, J. & Sensebe, L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. *Cell Stem Cell* **22**, 824–833 (2018).
14. Cesarz, Z., Funnell, J. L., Guan, J. & Tamama, K. Soft elasticity-associated signaling and bone morphogenic protein 2 are key regulators of mesenchymal stem cell spheroidal aggregates. *Stem Cells Dev.* **25**, 622–635 (2016).
15. Sart, S., Ma, T. & Li, Y. Preconditioning stem cells for in vivo delivery. *BioRes. Open Access* **3**, 137–149 (2014).
16. Lee, H. J., Gutierrez-Garcia, R. & Vilchez, D. Embryonic stem cells: a novel paradigm to study proteostasis? *FEBS J.* **284**, 391–398 (2017).
17. Searfoss, G. H., Paisley, B. M., Goldstein, K. M., Baker, T. K. & Willy, J. A. The integrated stress response regulates cell health of cardiac progenitors. *Toxicol. Sci.* **167**, 202–210 (2019).
18. Kroemer, G., Marino, G. & Levine, B. Autophagy and the integrated stress response. *Mol. Cell* **40**, 280–293 (2010).
19. Comley, K. & Fleck, N. A. A micromechanical model for the Young's modulus of adipose tissue. *Int. J. Solids Struct.* **47**, 2982–2990 (2010).
20. Jansen, L. E., Birch, N. P., Schiffman, J. D., Crosby, A. J. & Peyton, S. R. Mechanics of intact bone marrow. *J. Mech. Behav. Biomed. Mater.* **50**, 299–307 (2015).
21. Bijonowski, B. M., Daraiseh, S. I., Yuan, X. & Ma, T. Size-dependent cortical compaction induces metabolic adaptation in mesenchymal stem cell aggregates. *Tissue Eng. Part A* **25**, 575–587 (2019).
22. Liu, Y., Yuan, X., Munoz, N., Logan, T. M. & Ma, T. Commitment to aerobic glycolysis sustains immunosuppression of human mesenchymal stem cells. *Stem Cells Transl. Med.* **8**, 93–106 (2019).
23. Yuan, X., Rosenberg, J. T., Liu, Y., Grant, S. C. & Ma, T. Aggregation of human mesenchymal stem cells enhances survival and efficacy in stroke treatment. *Cytotherapy* **21**, 1033–1048 (2019).
24. Costa, M. H. G., McDevitt, T. C., Cabral, J. M. S., da Silva, C. L. & Ferreira, F. C. Tridimensional configurations of human mesenchymal stem/stromal cells to enhance cell paracrine potential towards wound healing processes. *J. Biotechnol.* **262**, 28–39 (2017).
25. Ruehle, M. A., Stevens, H. Y., Beedle, A. M., Guldborg, R. E. & Call, J. A. Aggregate mesenchymal stem cell delivery ameliorates the regenerative niche for muscle repair. *J. Tissue Eng. Regen. Med.* **12**, 1867–1876 (2018).
26. Sart, S. *et al.* Mapping the structure and biological functions within mesenchymal bodies using microfluidics. *Sci. Adv.* **6**, eaaw7853 (2020).
27. Follin, B. *et al.* Increased paracrine immunomodulatory potential of mesenchymal stromal cells in three-dimensional culture. *Tissue Eng. Part B Rev.* **22**, 322–329 (2016).
28. Liu, Y., Munoz, N., Tsai, A. C., Logan, T. M. & Ma, T. Metabolic reconfiguration supports reacquisition of primitive phenotype in human mesenchymal stem cell aggregates. *Stem Cells* **35**, 398–410 (2017).
29. Cesarz, Z. & Tamama, K. Spheroid culture of mesenchymal stem cells. *Stem Cells Int.* **2016**, 9176357 (2016).
30. Sart, S., Tsai, A.-C., Li, Y. & Ma, T. Three-dimensional aggregates of mesenchymal stem cells: cellular mechanisms, biological properties, and applications. *Tissue Eng. Part B Rev.* **20**, 365–380 (2014).
31. Bijonowski, B. M. *et al.* Aggregation-induced integrated stress response rejuvenates stemness of culture-expanded human mesenchymal stem cells. *Biotechnol. Bioeng.* **117**, 3136–3149 (2020).
32. Banfi, A. *et al.* Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy. *Exp. Hematol.* **28**, 707–715 (2000).
33. Yang, Y. K., Ogando, C. R., Wang See, C., Chang, T. Y. & Barabino, G. A. Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. *Stem Cell Res. Ther.* **9**, 131 (2018).
34. Bazhanov, N. *et al.* Intraperitoneally infused human mesenchymal stem cells form aggregates with mouse immune cells and attach to peritoneal organs. *Stem Cell Res. Ther.* **7**, 27 (2016).
35. Cho, R. J., Kim, Y. S., Kim, J. Y. & Oh, Y. M. Human adipose-derived mesenchymal stem cell spheroids improve recovery in a mouse model of elastase-induced emphysema. *BMB Rep.* **50**, 79–84 (2017).
36. Wobma, H., Liu, D. & Vunjak-Novakovic, G. Paracrine effects of mesenchymal stromal cells cultured in three-dimensional settings on tissue repair. *ACS Biomater. Sci. Eng.* **4**, 1162–1175 (2018).
37. Santos, J. M. *et al.* Three-dimensional spheroid cell culture of umbilical cord tissue-derived mesenchymal stromal cells leads to enhanced paracrine induction of wound healing. *Stem Cell Res. Ther.* **6**, 90 (2015).
38. Li, Y. *et al.* Three-dimensional spheroid culture of human umbilical cord mesenchymal stem cells promotes cell yield and stemness maintenance. *Cell Tissue Res.* **360**, 297–307 (2015).
39. Bartosh, T. J. *et al.* Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 13724–13729 (2010).
40. Tsai, A. C., Liu, Y., Yuan, X., Chella, R. & Ma, T. Aggregation kinetics of human mesenchymal stem cells under wave motion. *Biotechnol. J.* **12**, 1600448 (2017).
41. Bogdanova-Jatniece, A., Berzins, U. & Kozlovskas, T. Growth properties and pluripotency marker expression of spontaneously formed three-dimensional aggregates of human adipose-derived stem cells. *Int. J. Stem Cells* **7**, 143–152 (2014).
42. Bartosh, T. J., Ylostalo, J. H., Bazhanov, N., Kuhlman, J. & Prockop, D. J. Dynamic compaction of human mesenchymal stem/precursor cells (MSC) into spheres self-activates caspase-dependent IL1 signaling to enhance secretion of modulators of inflammation and immunity (PGE2, TSG6 and STC1). *Stem Cells* **31**, 2443–2456 (2013).
43. Suzuki, S. *et al.* Properties and usefulness of aggregates of synovial mesenchymal stem cells as a source for cartilage regeneration. *Arthritis Res. Ther.* **14**, R136 (2012).
44. Pennock, R. *et al.* Human cell dedifferentiation in mesenchymal condensates through controlled autophagy. *Sci. Rep.* **5**, 13113 (2015).
45. Kapetanou, M., Chondrogianni, N., Petrakis, S., Koliakos, G. & Gonos, E. S. Proteasome activation enhances stemness and lifespan of human mesenchymal stem cells. *Free Radic. Biol. Med.* **103**, 226–235 (2017).

Acknowledgements

In fond memory, the authors acknowledge the guidance provided by Professor Teng Ma, who passed away in 2019. The authors would like to thank Dr. Brian Washburn and Ms. Kristina Poduch of FSU Department of

Biomedical Sciences for performing qRT-PCR experiments. This work was supported by National Science Foundation (CBET #1743426) and NIH (R01NS102395-01A1). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions

B.B. performed most of the experiments and did most of data analysis. He also wrote initial draft of the manuscript. X.Y. performed some culture experiments, helped the manuscript revision, and reviewed the manuscript. R.J. helped some cell culture and sample preparation, and reviewed the manuscript. Y.L. and S.G. conceived the projects, supervised the experiments and data analysis, and revised the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-020-77288-4>.

Correspondence and requests for materials should be addressed to B.M.B. or Y.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020